AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage

• The company said that its trial data also show that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.
• An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, Anavex said.
• This includes cognition, activities of daily life, and global clinical cognitive and functional outcome.

Anavex Life Sciences Corp. (AVXL) on Monday reported new data about its Alzheimer’s drug blarcamesine, suggesting a slowdown in brain shrinkage.

At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III program, indicating that preservation of brain volume is linked to improved patient outcomes. The drug remains investigational and has not been approved by regulators.

Anavex shares were up more than 13% in Monday’s opening trade.

What Does The Data Show?

Anavex stated that the new data points to a reduction in brain volume loss over time. Brain shrinkage is a key marker of Alzheimer’s progression.

“The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR3 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Timo Grimmer, member of the Anavex Scientific Advisory Board.

The company said that its trial data also shows that patients with wild-type SIGMAR1 and COL24A1 genes may experience substantially greater clinical and structural benefit from blarcamesine.

An analysis of MRI biomarkers showed a strong and consistent correlation between reduced brain atrophy and improvements across primary and secondary clinical endpoints, including cognition, activities of daily life, and global clinical cognitive and functional outcome.

“The consistent relation between structural preservation of brain volume and functional outcomes further drives our dedication to developing a novel disease-modifying Alzheimer’s treatment with our oral blarcamesine,” said Anavex CEO Christopher U. Missling.

What Does Anavex Do?

Anavex is a New York-based biopharmaceutical that is involved in the development of therapeutics for the treatment of various disorders, including Alzheimer’s disease, Parkinson’s disease, and schizophrenia, among others.

The company’s preclinical studies of blarcamesine showed that the oral drug candidate has the potential to halt or reverse the course of Alzheimer’s disease.

How Did Stocktwits Users React?

Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.

One bullish user said that Anavex’s brain volume preservation data is “incredibly exciting.”

AVXL stock is up 26% year-to-date, but down 54% over the past 12 months. The SPDR S&P Biotech ETF (XBI) is up 41% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 23%.

Also See: Gold Price Recovers To $4,450 On Trump’s Iran Attack Pause – But Yellow Metal Is Still Down 15% In A Month After ‘Sell Everything’ Rout

For updates and corrections, email newsroom[at]stocktwits[dot]com.